Hemostemix Stock Today
| HEM Stock | CAD 0.08 0.01 5.88% |
Performance8 of 100
| Odds Of DistressLess than 46
|
Hemostemix is selling for under 0.08 as of the 24th of November 2024; that is 5.88 percent decrease since the beginning of the trading day. The stock's lowest day price was 0.08. Hemostemix has 46 percent odds of going through some form of financial distress in the next two years and did not have a very good performance for investor during the last 90 trading days. Equity ratings for Hemostemix are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 5th of December 2022 and ending today, the 24th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | Category Healthcare | Classification Health Care |
Hemostemix Inc., a clinical-stage biotechnology company, develops, manufactures, and commercializes blood-derived cell therapies for medical conditions in Canada. It is also developing various types of cells products, such as synergetic cell precursors, myocardial cell precursors, and neural cell precursors. The company has 123.98 M outstanding shares of which 451 shares are currently shorted by private and institutional investors with about 0.0 days to cover all short positions. More on Hemostemix
Hemostemix Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Hemostemix's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Hemostemix or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
Hemostemix's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Hemostemix's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Debt LevelsHemostemix can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Hemostemix's financial leverage. It provides some insight into what part of Hemostemix's total assets is financed by creditors.
| |||||
Hemostemix (HEM) is traded on TSX Venture Exchange in Canada and employs 6 people. Hemostemix is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 9.92 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Hemostemix's market, we take the total number of its shares issued and multiply it by Hemostemix's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Hemostemix classifies itself under Biotechnology sector and is part of Health Care industry. The entity has 123.98 M outstanding shares of which 451 shares are currently shorted by private and institutional investors with about 0.0 days to cover all short positions.
Hemostemix has accumulated about 49.36 K in cash with (1.5 M) of positive cash flow from operations.
Check Hemostemix Probability Of Bankruptcy
Ownership AllocationHemostemix has a total of 123.98 Million outstanding shares. Hemostemix retains 9.54 (percent) of its outstanding shares held by insiders and 0.0 (percent) owned by outside corporations. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Hemostemix Ownership Details
Hemostemix Risk Profiles
Although Hemostemix's alpha and beta are two of the key measurements used to evaluate Hemostemix's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 8.54 | |||
| Semi Deviation | 8.51 | |||
| Standard Deviation | 11.74 | |||
| Variance | 137.88 |
Hemostemix Stock Against Markets
| HEM | 5.88 |
|
| Compare Correlations |
Be your own money manager
Our tools can tell you how much better you can do entering a position in Hemostemix without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Rebalancing Now
Portfolio RebalancingAnalyze risk-adjusted returns against different time horizons to find asset-allocation targets |
| All Next | Launch Module |
Hemostemix Corporate Management
Elected by the shareholders, the Hemostemix's board of directors comprises two types of representatives: Hemostemix inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Hemostemix. The board's role is to monitor Hemostemix's management team and ensure that shareholders' interests are well served. Hemostemix's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Hemostemix's outside directors are responsible for providing unbiased perspectives on the board's policies.
| BA BA | President, CoFounder | Profile | |
| MD Sr | Chief Officer | Profile | |
| Thomas CA | Pres Inc | Profile | |
| Peter Pavlin | Vice Operations | Profile | |
| Cameron Cole | Head Relations | Profile | |
| Christina CPA | Interim Officer | Profile |
Additional Tools for Hemostemix Stock Analysis
When running Hemostemix's price analysis, check to measure Hemostemix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hemostemix is operating at the current time. Most of Hemostemix's value examination focuses on studying past and present price action to predict the probability of Hemostemix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hemostemix's price. Additionally, you may evaluate how the addition of Hemostemix to your portfolios can decrease your overall portfolio volatility.